Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Cancer Research

• Publication date

  1998-11-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 9810004
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Farnesyltransferase inhibitors and anti-Ras therapy

  2005cited by this paper
• Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice

  1999cited by this paper
• Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity.

  1998cited by this paper
• Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.

  1998cited by this paper
• A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis

  1998cited by this paper
• Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.

  1998cited by this paper
• Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation.

  1997cited by this paper
• Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo *

  1997cited by this paper
• Pharmacokinetic screening for the selection of new drug discovery candidates is greatly enhanced through the use of liquid chromatography-atmospheric pressure ionization tandem mass spectrometry.

  1997cited by this paper
• Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?

  1997cited by this paper
• Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I*

  1997cited by this paper
• Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment.

  1997cited by this paper
• K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors*

  1997cited by this paper
• Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.

  1996cited by this paper
• Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase.

  1996cited by this paper
• Stimulation of Membrane Ruffling and MAP Kinase Activation by Distinct Effectors of RAS

  1996cited by this paper
• Section Review Oncologic, Endocrine & Metabolic: Farnesyl-protein transferase inhibitors in early development

  1996cited by this paper
• Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in Vitro(*)

  1995cited by this paper
• Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.

  1995cited by this paper
• Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.

  1995cited by this paper
• A Non-peptide Mimetic of Ras-CAAX: Selective Inhibition of Farnesyltransferase and Ras Processing (*)

  1995cited by this paper
• Novel Tricyclic Inhibitors of Farnesyl Protein Transferase

  1995cited by this paper
• A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.

  1995cited by this paper
• In wap-ras transgenic mice, tumor phenotype but not cyclophosphamide-sensitivity is affected by genetic background.

  1995cited by this paper
• Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

  1995cited by this paper
• Pseudodipeptide inhibitors of protein farnesyltransferase.

  1995cited by this paper
• Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

  1995cited by this paper
• Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.

  1994cited by this paper
• Pseudopeptide inhibitors of Ras farnesyl-protein transferase.

  1994cited by this paper
• The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation.

  1994cited by this paper
• Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells.

  1993cited by this paper
• Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.

  1993cited by this paper
• Peptidomimetic inhibitors of Ras farnesylation and function in whole cells.

  1993cited by this paper
• Function and regulation of ras.

  1993cited by this paper
• Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.

  1993cited by this paper
• Evaluation of the wap-ras transgenic mouse as a model system for testing anticancer drugs.

  1992cited by this paper
• Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity.

  1992cited by this paper
• Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene.

  1991cited by this paper
• Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation.

  1990cited by this paper
• Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans.

  1989cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice.

  1987cited by this paper
• ras genes.

  1987cited by this paper
• Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication.

  1982cited by this paper

• Cancer cell dynamics on silica fibers

  2025cites this paper
• 3.6.5.2 Small monomeric GTPases in GtoPdb v.2025.3

  2025cites this paper
• Farnesylation-Dependent Kinetochore Targeting of CENP-F Is Essential for Oocyte Meiotic Progression and Female Fertility.

  2025cites this paper
• RAS subfamily in GtoPdb v.2025.3

  2025cites this paper
• 3.6.5.2 Small monomeric GTPases in GtoPdb v.2025.4

  2025cites this paper
• Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D

  2025cites this paper
• Targeting the RAS upstream and downstream signaling pathway for Cancer treatment.

  2024cites this paper
• 3.6.5.2 Small monomeric GTPases in GtoPdb v.2023.1

  2023cites this paper
• Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?

  2023cites this paper
• Drugging KRAS: current perspectives and state-of-art review

  2022cites this paper
• Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.

  2022cites this paper
• Hepatitis D virus: Improving virological knowledge to develop new treatments.

  2022cites this paper
• A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives.

  2022cites this paper
• Structural optimization of novel Ras modulator for treatment of Colorectal cancer by promoting β-catenin and Ras degradation.

  2022cites this paper
• Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice

  2022cites this paper
• Targeting HRAS in Head and Neck Cancer

  2022cites this paper
• Epidemiology, presentation, and therapeutic approaches for hepatitis D infections

  2022cites this paper
• Ras Signaling in Breast Cancer.

  2021cites this paper
• Targeting Small GTPases and Their Prenylation in Diabetes Mellitus

  2021cites this paper
• Novel Therapies of Hepatitis B and D

  2021cites this paper
• The Role of Kinase Inhibitors in Cancer Therapies

  2021cites this paper
• The interplay between Ras, Autophagy and cancer

  2021cites this paper
• An overview on natural farnesyltransferase inhibitors for efficient cancer therapy

  2020cites this paper
• Ras and Rap1: A tale of two GTPases.

  2019cites this paper
• From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers

  2019cites this paper
• DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma

  2019cites this paper
• Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine

  2018cites this paper
• Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.

  2018cites this paper
• Strategies for the treatment of HBV/HDV

  2018cites this paper
• The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review.

  2018cites this paper
• Role of Hypoxia-Inducible Factor (HIF) in the Initiation of Cancer and Its Therapeutic Inhibitors

  2017cites this paper
• Cholesterol synthesis requirements in oligodendrocyte development and myelination

  2017influential citation
• Regulation of Ras signaling and function by plasma membrane microdomains.

  2017cites this paper
• Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting.

  2017cites this paper
• Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells

  2017cites this paper
• Search for Inhibitors of Ras-Driven Cancers

  2017cites this paper
• Searching for the Chokehold of NRAS Mutant Melanoma.

  2016influential citation
• Past, Present, and Future of Targeting Ras for Cancer Therapies.

  2016cites this paper
• Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation.

  2016cites this paper
• The renewed battle against RAS-mutant cancers

  2016cites this paper
• Discovery of Novel Tricyclic Thiazepine Derivatives as Anti-Drug-Resistant Cancer Agents by Combining Diversity-Oriented Synthesis and Converging Screening Approach.

  2016cites this paper
• Role of angiogenic factors of herbal origin in regulation of molecular pathways that control tumor angiogenesis

  2016cites this paper
• Targets in anticancer research--A review.

  2015cites this paper
• Tumour Angiogenesis and Angiogenic Inhibitors: A Review.

  2015cites this paper
• BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo

  2015cites this paper
• Bcc 1 , the novel antineoplastic nanocomplex , showed potent anticancer effects in vitro and in vivo

  2015cites this paper
• Bcc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo

  2015cites this paper
• The Role of Prenylation in Vascular Calcification

  2014cites this paper
• Farnesyltransferase inhibitors: CAAX mimetics based on different biaryl scaffolds.

  2014cites this paper
• The role of the farnesyltransferase inhibitor lonafarnib in the treatment of Progeria

  2014cites this paper
• Ras and autophagy in cancer development and therapy

  2014cites this paper
• General aspects of protein prenylation The importance of FT and GGT 1 for normal physiology and tumorigenesis : lessons from knockout mice

  2014cites this paper
• Mutation of 3-Hydroxy-3-Methylglutaryl CoA Synthase I Reveals Requirements for Isoprenoid and Cholesterol Synthesis in Oligodendrocyte Migration Arrest, Axon Wrapping, and Myelin Gene Expression

  2014influential citation
• Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas

  2013cites this paper
• in therapy Farnesyltransferase inhibitors in hematologic malignancies: new horizons

  2013cites this paper
• SCH66336 Overcoming STI571 resistance with the farnesyl transferase inhibitor

  2013cites this paper
• Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

  2013cites this paper
• Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections.

  2013cites this paper
• Targeting the RAS oncogene

  2013cites this paper
• Inhibition of Angiogenesis and Tumor Growth by Sch221153, Updated Version Cited Articles Citing Articles E-mail Alerts Inhibition of Angiogenesis and Tumor Growth by Sch221153, a Dual ␣ V ␤ 3 and ␣ V ␤ 5 Integrin Receptor Antagonist

  2013cites this paper
• transgenic mice with the farnesyl transferase inhibitor SCH66336 Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190

  2013cites this paper
• inhibitors stem and progenitor cells and synergizes with tyrosine kinase BMS-214662 potently induces apoptosis of chronic myeloid leukemia

  2013cites this paper
• chronic myeloid leukemia BCR/ABL-induced murine leukemia and primary cells from patients with Activity of the farnesyl protein transferase inhibitor SCH66336 against

  2013cites this paper
• Oligomerization of rab/effector complexes in the regulation of vesicle trafficking.

  2013cites this paper
• Translational Oncogenomics and Human Cancer Interactome Networks: Recent Developments, Complex System Dynamic Approaches and Novel Techniques

  2012cites this paper
• Clinical Trials in Cancer and Pharmacogenomics: A Critical Evaluation

  2012cites this paper
• Identifying genes that are required for the maintenance of pancreatic ductal adenocarcinoma

  2012cites this paper
• Mechanistic Investigation of Tolfenamic Acid, Betulinic Acid, and Aspirin in Anti-Cancer Therapy

  2012cites this paper
• Protein farnesylation and disease

  2012cites this paper
• A multiplicity of anti‐invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer

  2012cites this paper
• Lonafarnib for cancer and progeria

  2012cites this paper
• Farnesyltransferase Inhibitors

  2012cites this paper
• Dapson in heterocyclic chemistry, part V: synthesis, molecular docking and anticancer activity of some novel sulfonylbiscompounds carrying biologically active dihydropyridine, dihydroisoquinoline, 1,3-dithiolan, 1,3-dithian, acrylamide, pyrazole, pyrazolopyrimidine and benzochromenemoieties.

  2012cites this paper
• Farnesyl transferase expression determines clinical response to the docetaxel‐lonafarnib combination in patients with advanced malignancies

  2011cites this paper
• Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo.

  2011cites this paper
• Translational Oncogenomics and Human Cancer Interactome Networks : Techniques and Complex System Dynamic Approaches

  2011cites this paper
• treatment for hematologic malignancies? Targeting the Ras signaling pathway: a rational, mechanism-based

  2011cites this paper
• Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective

  2011cites this paper
• Human Tumor Xenograft Efficacy Models

  2011cites this paper
• Combination therapy for the treatment of pancreatic cancer.

  2011cites this paper
• Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.

  2011cites this paper
• The Analysis of Bionetwork Dynamics 2. Techniques and Application Examples 2.1. DNA Microarrays 2.2. Oligonucleotide Arrays 2.3. Gene Expression – Microarray Data Analysis 2.4. Protein Microarrays 2.5. Tissue Arrays 2.6. Fluorescence Correlation Spectroscopy and Fluorescence Cross--Correlation Spect

  2011cites this paper
• A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer

  2011cites this paper
• Farnesyl Transferase Inhibitors: From Targeted Cancer Therapeutic to a Potential Treatment for Progeria

  2011cites this paper
• Therapeutic strategies for targeting ras proteins.

  2011cites this paper
• Targeting protein prenylation for cancer therapy

  2011cites this paper
• Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors

  2011cites this paper
• Angiogenesis Inhibitors: Current Strategies and Future Prospects

  2010cites this paper
• The molecular targets for the diagnosis and treatment of pancreatic cancer.

  2010cites this paper
• BESCT (Biology, Education, Screening, Chemoprevention and Treatment) Program

  2010cites this paper
• Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer

  2010cites this paper
• Farnesyltransferase inhibitors: where are we now?

  2010influential citation
• Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.

  2010cites this paper
• Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.

  2010cites this paper
• CUG2, a novel oncogene confers reoviral replication through Ras and p38 signaling pathway

  2010cites this paper
• Overcoming multidrug-resistance in cancer: statins offer a logical candidate.

  2010cites this paper
• A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model.

  2010cites this paper
• The Farnesyltransferase Inhibitor LB42708 Suppresses Vascular Endothelial Growth Factor-Induced Angiogenesis by Inhibiting Ras-dependent Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase/Akt Signal Pathways

  2010influential citation
• Signal Transduction Inhibitors in the Treatment of Breast Cancer

  2009cites this paper
• Farnesyltransferase inhibitor as anticancer agent.

  2009cites this paper